晚期非小细胞肺癌图像引导再活检的分子充分性:单中心经验
该单中心回顾性分析纳入2011–2014年103例接受经胸图像引导肺再活检的患者,分析其中66例NSCLC再活检。病理成功率为87.1%,组织学不一致率为23.1%(12/52),分子检测前充分性为78.8%(52/66),基因分型后分子充分性为87.1%(182/209)。再活检在63.6%的病例中影响了临床决策。
要点
- 再活检病理成功率为87.1%,分子检测前充分性为78.8%。
- 组织学不一致率为23.1%(12/52例可评估病例)。
- 再活检在63.6%的病例中影响了临床决策。
核心结论
- 该中心验证了再活检的病理和分子充分性率,并证明其在常规决策中的临床效用。
研究设计与样本
- 单中心回顾性病例笔记分析,纳入2011–2014年接受图像引导肺再活检的患者,共识别并分析66例NSCLC再活检。
主要发现
- 病理成功率为87.1%。
- 组织学不一致率为23.1%(12/52例可评估病例)。
- 分子检测前充分性为78.8%(52/66)。
- 基因分型后分子充分性为87.1%(182/209)。
- 再活检在63.6%的病例中影响了临床决策。
关键数值与推荐
- 52例充分样本中51例送分子分析,共分析209个基因(包括EGFR、ALK、KRAS、BRAF、DDR2、NRAS、ROS1和RET)。
- 识别出20个新的潜在可靶向突变,13/66例(19.7%)患者因此开始接受新的靶向治疗。
- 并发症发生率:气胸15%,需胸腔引流的气胸3%,咯血8%。
临床怎么用
- 在晚期NSCLC中,图像引导再活检可用于常规决策时的分子再检测。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In the era of biomarker-driven systemic therapy for advanced NSCLC, the role of routine repeated biopsies for decision making outside EGFR-mutant disease remains unproven. We report our center's experience of safety and adequacy for molecular retesting of tumor material obtained from image-guided lung rebiopsies in NSCLC. METHODS: We performed a retrospective case note analysis of patients undergoing image-guided lung rebiopsies at a single cancer center between 2011 and 2014. The primary objective was to determine the pathological success rate. Secondary and exploratory objectives were to determine technical success rate, histological concordance, molecular adequacy, genotypes identified, and complication rate. RESULTS: In all, 103 patients underwent transthoracic image-guided procedures. A total of 66 rebiopsies in NSCLC were identified and analyzed. The pathological success rate was 87.1%. A high histological discordance rate was observed (12 of 52 evaluable cases [23.1%]). Pretest molecular adequacy as determined by the lung pathologist was 78.8% (52 of 66). Of 52 adequate samples 51 were sent for molecular analysis, with a total of 209 genes analyzed (including EGFR, ALK receptor tyrosine kinase gene [ALK], KRAS, BRAF, dicoidin domain receptor tyrosine kinase 2 gene [DDR2], NRAS, ROS1, and rearranged during transfection proto-oncogene gene [RET]). The rate of postgenotyping molecular adequacy was 87.1% (182 of 209). Overall, 20 new potentially actionable mutations were identified, with 13 of 66 patients (19.7%) starting to receive new targeted treatment as a result. Overall, rebiopsies informed clinical decision making in 63.6% of cases. The rates of complications were 15% for pneumothorax, 3% for pneumothorax requiring chest drain, and 8% for hemoptysis. CONCLUSIONS: We have validated the pathological and molecular adequacy rates of rebiopsies and demonstrated clinical utility in routine decision making.
引用
- Tokaca N, Barth S, O'Brien M, et al. Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Non-Small Cell Lung Cancer: A Single-Center Experience. J Thorac Oncol. 2017. PMID: 28989040. doi:10.1016/j.jtho.2017.09.1958
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。